Article
MedImmune and Incyte Announce Immuno-Oncology Collaboration
MedImmune and Incyte are planning the initiation of a collaborative Phase I/II study to test the efficacy of MedImmune's PD-L1 inhibitor MEDI4736 with Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.
Incyte Corporation and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into a clinical study collaboration. The Phase I/II oncology study will evaluate the efficacy and safety of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.
Both MEDI4736 and INCB24360 are investigational compounds that are part of a new class of cancer treatments known as immunotherapies, which use the body's own immune system to help fight cancer. MEDI4736 blocks the signals that help tumors avoid detection by the immune system, countering the tumor’s immune-evading tactics, while INCB24360 enhances the ability of immune cells to combat the tumor. Preclinical evidence suggests that the combination of these two agents may lead to an enhanced anti-tumor immune response.
Source: MarketWatch
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
